Clinical trials: Cholangiocarcinoma
Bile Duct Cancer, Cholangiocarcinoma
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.
- Conditions
- Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
- Trial name
- NCT05655949
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hepatocellular Carcinoma
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC)…
- Trial name
- PROACTIF (NCT04069468)
- Testing
- TheraSphere
- Where
- 37 sites in France
- Volunteers
- 1,247 people
- Sponsor
- Boston Scientific Corporation
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Intrahepatic Cholangiocarcinoma
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
This study is a single-arm, open-label, exploratory clinical trial, with the primary objective to evaluate the efficacy and safety of the Neoantigen Vaccine plus capecitabine for the treatment of high-intermediate risk recurrent…
- Trial name
- NCT06406816
- Testing
- Neoantigen Vaccine plus Capecitabine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yongyi Zeng
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery.
- Trial name
- NCT06730009
- Testing
- SLOG + Allogeneic NK cell, SLOG chemotherapy
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Medigen Biotechnology Corporation
Cholangiocarcinoma
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.
- Trial name
- NCT06341764
- Testing
- Durvalumab 1120 mg, Durvalumab 1500 mg, Tremelimumab i.v. at 300 mg
- Where
- 6 sites in Italy
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute, Naples
Advanced Solid Tumors, Urothelial Carcinoma
A Study of ICP-192 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations.
- Conditions
- Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
- Trial name
- NCT04565275
- Testing
- Drug ICP-192
- Where
- 16 sites in United States, Australia
- Volunteers
- 45 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Cholangiocarcinoma, Gallbladder Carcinoma
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with malignant hilar biliary obstruction who are treated by unilateral or bilateral stenting.
- Conditions
- Cholangiocarcinoma, Gallbladder Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02649712
- Testing
- biliary stent
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Xuzhou Central Hospital
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Liver Metastases
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE.
- Trial name
- NCT07717437
- Where
- 31 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Maastricht University Medical Center
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma (Icc)
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor…
- Trial name
- NCT07304388
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Bile Duct Stricture, Bile Duct Cancer
Metal Stents (Moving Cell Stent) for Inoperable Tumors of the Bile Duct Tract
In this feasibility study (non-randomized), the applicability of a new "moving cell" biliary stents (by HILZO) in Klatskin tumors (bile duct obstruction) will be investigated.
- Trial name
- NCT03788655
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Johannes Vermehren
Gallbladder Cancer, Cholangiocarcinoma
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
The goal of this clinical trial is to evaluate the efficacy and safety of combining Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab in adults aged 18-75 years with advanced unresectable biliary tract malignancies…
- Trial name
- GALENT-BT (NCT06963060)
- Testing
- Gemcitabine nab-PaclitaxelLenvatinibTislelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Wei Gong
Intrahepatic Cholangiocarcinoma
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver malignancies. Surgical treatment is the first choice. However, for patients without surgical indications, the benefits of conventional chemoradiotherapy are…
- Trial name
- NCT03633773
- Testing
- MUC-1 CART cell immunotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cholangiocarcinomas
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)
The purpose of this study is to determine the efficacy of panitumumab plus cisplatin/gemcitabine (CisGem) combination chemotherapy in KRAS wild-type biliary tract cancer patients without systemic pre-treatment, compared to the…
- Trial name
- PiCCA (NCT01320254)
- Testing
- Cisplatin, Gemcitabine, Panitumumab, Cisplatin, Gemcitabine
- Where
- 16 sites in Germany
- Volunteers
- 93 people
- Sponsor
- Hannover Medical School
Advanced Intrahepatic Cholangiocarcinoma
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
This study is a randomized, controlled, open-label, single center clinical study. This study is designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Combined With GC versus Sintilimab Combined With GC as…
- Trial name
- ITUS (NCT07152769)
- Testing
- Iparomlimab and Tuvonralimab + GC, Sintilimab + GC
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Pancreatic Cancer Non-resectable, Bile Duct Cancer
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
The goal of this randomized controlled trial is to compare uncovered, partially covered, and fully covered self-expandable metal stents (SEMS) in the palliative treatment of distal malignant biliary obstruction in a Swedish…
- Conditions
- Pancreatic Cancer Non-resectable, Bile Duct Cancer, Papillary Carcinoma, Duodenal Cancer
- Trial name
- NCT06453590
- Testing
- Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
- Where
- 12 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- Region Stockholm
Cholangiocarcinoma, Biliary Stricture
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis
Cholangiocarcinoma remains difficult to diagnose because of the limited sensitivity of currently available endobiliary sampling techniques.
- Trial name
- EYE/SPY (NCT07620080)
- Testing
- EYEMAX® cholangioscopy system, SPYGLASS™ DS system
- Volunteers
- 120 people
- Sponsor
- David KARSENTI